Clinical Trial Update: Fluorescence Imaging of Adalimumab-680LT and Risankizumab-800CW in Inflammatory Bowel Disease [Phase 1, Phase 2]

View source ↗

Summary

This trial update describes fluorescence imaging agents Adalimumab-680LT and Risankizumab-800CW evaluated in inflammatory bowel disease (ulcerative colitis and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Ulcerative Colitis

Drugs mentioned

• Adalimumab-680LT (adalimumab)
• Risankizumab-800CW (risankizumab-800CW)

Snippet

Sponsor: University Medical Center Groningen | Conditions: Ulcerative Colitis (UC), Crohn Disease (CD) | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING